SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
淡淡向卉
Lv1
10 积分
2023-12-20 加入
最近求助
最近应助
互助留言
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
10天前
已完结
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
10天前
已完结
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
1个月前
已完结
Exploring the next generation of antibody–drug conjugates
1个月前
已完结
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
3个月前
已完结
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
3个月前
已完结
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
3个月前
已完结
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
3个月前
已完结
Nectin-4: a Tumor Cell Target and Status of Inhibitor Development
4个月前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
4个月前
已完结
没有进行任何应助
谢谢
3个月前
谢谢
3个月前
谢谢
3个月前
感谢
4个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论